The 7 references in paper S. Zyryanov K., Z. Aisanov R., С. Зырянов К., З. Айсанов Р. (2014) “Воспроизведенные ингаляционные лекарственные средства: как оценить их свойства? // Generic inhaled drugs: how to evaluate their properties?” / spz:neicon:pulmonology:y:2012:i:3:p:115-118

1
FDA. Orange book: Approved drug products with therapeutic equivalence evaluations. 30thed.; 2010.
(check this in PDF content)
2
Белоусов Ю.Б., Зырянов С.К.Дженерики и бренды: pro et contra. Качеств. клини. практ. 2003; 2: 95–100.
(check this in PDF content)
3
Daley'Yates P.T., Parkins D.A.Establishing bioequivalence for inhaled drug, weighing the evidence. Expert. Opin. Drug Deliv. 2011; 1: 112.
(check this in PDF content)
4
European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents Doc. Ref. CPMP/ EWP/4151/00 Rev. 1. Jan. 2009. London; 2009.
(check this in PDF content)
5
Lawrence M., Wolfe J., Webb D.R. et al.Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am. J. Respir. Crit. Care Med. 1997; 156: 744–751.
(check this in PDF content)
6
Clearie K.I., Williamson P.A., Vaidyanathan S. et al. Systemic bioavailability of hydrofluoroalkane formulation of fluticasone / salmeterol in healthy volunteers via pMDI alone and spacer. Br. J. Clin. Pharmacol. 2010; 69: 637–644.
(check this in PDF content)
7
Информационное письмо-обращение экспертов Российского респираторного общества к врачам первичного звена и специалистам в области пульмонологии. Пульмонология 2011; 6; 119. Информация об авторах
(check this in PDF content)